Iselin, NJHilton WoodbridgeMay 16 – 17, 2012

2012Pharmaceutical/Biotech Accounting & Reporting Update Conference

Get the most recent updates on changing regulations,

industry trends and the latest life sciences accounting

and reporting best practices. Discover how health care

reform, the credit crisis, the SEC and international tax

planning will impact the financial reporting of pharma-

ceutical and biotech companies. Plus, gain technical

guidance from top level pharmaceutical finance officers

and government regulators in this highly focused two-

day conference.

Designed for financial professionals

in the pharmaceutical and biotechnology

industries.

AGENDA HIGHLIGHTS

< The current environment and key emerging trends

< Health care reform update

< Regulatory update: aggregate spend reporting and the Sunshine Act

< Deal-making in the industry

< M&A activity: current trends and expectations in the industry

< Valuation considerations

< FASB and technical accounting update

< Revenue recognition and leases

< Leadership in pharmaceuticals and biotechnology

< Projecting pharmaceutical business trends

< Outlook for the global pharmaceuticals industry

• SEC comment letters

AMERICA’S LEADER IN CONTINUING PROFESSIONAL EDUCATION

THIS PROGRAM WILL BE SIMULTANEOUSLY PRESENTED AS A LIVE WEBCAST

Register Today < 1-800-544-1114

AMERICA’S LEADER IN CONTINUING PROFESSIONAL EDUCATION

May 16, 2012

Deluxe Continental Breakfast & Registration8:00 – 8:45 AM

Chairman’s Welcome & Opening Remarks8:45 – 9:00 AM

The Current Environment & Key Emerging Trends9:00 – 10:15 AM< Growth market and emerging opportunities

< Market and health care trends

< Scientific and technological trends

< In-house discovery vs. in-licensing and strategic alliances

Break10:15 – 10:30 AM

Health Care Reform Update10:30 AM – 12:00 PM< New proposed rules for AMP and BP and the overall

impact to the Medicaid Drug Program

< Potential impact on AMP calculation methodology and Medicaid rebate liabilities

< Emerging industry best practices to address the proposed rules

< Preparations that will be necessary to comply with proposed new rules

< Best practices for compliance

< Systems and procedural requirements

< Documentation and testing practices

Luncheon12:00 – 12:45 PM

Regulatory Update: Aggregate Spend Reporting & the Sunshine Act12:45 – 1:45 PM< Update/status of the proposed changes to the

Sunshine Act

< Issues within the Spend Reporting Compliance Continuum

< Aggregate spend disputes and inquiries from health care professionals

Break1:45 – 2:00 PM

Deal-Making in the Industry2:00 – 3:15 PM< M&A activity: current trends and expectations in

the industry

< M&A best practices – Initial interest and due diligence – Contract support – Closing and integration

< Key diligence areas of focus and value drivers: US vs. ex-US emerging markets

Break3:15 – 3:30 PM

Valuation Considerations 3:30 – 5:00 PM< M&A and intangible asset valuations

< Changes to the AICPA practice aid for IPR&D

< Alternative methodologies for IPR&D valuation

< Discount rate considerations

< Inventory valuation and complexities in the pharmaceutical industry

< Contingent consideration: accounting treatment and royalty arrangements

< Day Two impairment considerations and “Step 0”

Cocktail Reception5:00 – 6:00 PM

CONFERENCE AGENDA

cpe credit: 16 hours < price: $1445

2012Pharmaceutical/Biotech Accounting & Reporting Update Conference

May 17, 2012

Deluxe Continental Breakfast8:00 – 8:30 AM

FASB & Technical Accounting Update: Roundtable Brief (Part I)8:30 – 10:00 AM< Revenue recognition and leases

< Collaborations, joint ventures and other alliances

< Current rules and new developments

Break10:00 – 10:15 AM

FASB & Technical Accounting Update: Roundtable Brief (Part II)10:15 AM – 12:00 PM< Non-GAAP measures

< Loss contingencies

< Income taxes, including repatriation of earnings

< Impairments

Luncheon12:00 – 1:00 PM

Leadership in Pharmaceuticals & Biotechnology: Executive Roundtable1:00 – 2:15 PM< Life cycle management issues

< The impact of health care reform on the pharmaceutical and biotechnology industries

< Drug portfolio diversification

< Exclusivity losses

< Projecting pharmaceutical business trends in highly competitive markets

Break2:15 – 2:30 PM

Outlook for the Global Pharmaceuticals Industry2:30 – 3:30 PM< Outlook for foreign pharmaceutical sector

< Global rating methodology for generic pharmaceuticals manufacturers

< Regulatory environment and pressure on pharmaceutical companies

< Late-stage pipeline considerations and patent risk exposures

< Impact from exclusivity losses

Break3:30 – 3:45 PM

SEC Comment Letters3:45 – 5:00 PM< Key SEC staff messages

< Current issues impacting pharmaceutical companies

< Past areas of SEC staff focus

< Potential outcomes of a comment letter

< How does a review result in enforcement investigation?

< Best practices footnote disclosures

< Responding to the staff

Conference Ends5:00 PM

CONFERENCE SPEAKERS

Ben Barrameda, Partner, Cumulus Consulting LLC

Glenn Hunzinger, Transactions Services Director, PwC

David Levi, Director of Technical Accounting, Bristol-Myers Squibb

Mark Linver, Managing Director, Huron Life Sciences

Debbie Paul, Senior Vice President North America, EvaluatePharma USA, Inc.

John Pennett, Partner-in-Charge, Life Sciences Group, EisnerAmper

Reuven Pinsky, Director, Transaction Services, PwC

Jeffrey Schaeffer, Senior Manager, National Professional Practice, Ernst & Young LLP

Jay Seliber, Assurance Partner, PwC

Donald Walker, Senior Managing Director, FTI Consulting

Kristina Winch, USP Technical Accounting and Controls Manager, Bristol-Myers Squibb

…and more!

Register Today

1-800-544-1114